DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,798 filers reported holding DANAHER CORPORATION in Q2 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,166,665 | +3.3% | 16,794 | -0.1% | 0.64% | +7.4% |
| Q2 2023 | $4,035,386 | -4.8% | 16,814 | 0.0% | 0.59% | -6.5% |
| Q1 2023 | $4,237,777 | -5.0% | 16,814 | 0.0% | 0.63% | -10.8% |
| Q4 2022 | $4,462,700 | +3.2% | 16,814 | +0.4% | 0.71% | -10.4% |
| Q3 2022 | $4,324,000 | +2.7% | 16,741 | +0.8% | 0.79% | +7.9% |
| Q2 2022 | $4,211,000 | -16.6% | 16,610 | -3.6% | 0.73% | -4.8% |
| Q1 2022 | $5,052,000 | -11.3% | 17,223 | -0.5% | 0.77% | -10.0% |
| Q4 2021 | $5,697,000 | +8.8% | 17,315 | +0.6% | 0.86% | +0.1% |
| Q3 2021 | $5,238,000 | +13.3% | 17,205 | -0.1% | 0.86% | +11.9% |
| Q2 2021 | $4,624,000 | +19.2% | 17,230 | 0.0% | 0.76% | +6.1% |
| Q1 2021 | $3,878,000 | +1.3% | 17,230 | -0.0% | 0.72% | -7.2% |
| Q4 2020 | $3,829,000 | +3.0% | 17,236 | -0.1% | 0.78% | -11.6% |
| Q3 2020 | $3,716,000 | +15.9% | 17,259 | -4.8% | 0.88% | +3.4% |
| Q2 2020 | $3,206,000 | +27.6% | 18,131 | -0.1% | 0.85% | -0.2% |
| Q1 2020 | $2,512,000 | -12.2% | 18,146 | -2.6% | 0.85% | +26.8% |
| Q4 2019 | $2,860,000 | +6.3% | 18,635 | 0.0% | 0.67% | -2.0% |
| Q3 2019 | $2,691,000 | +0.9% | 18,635 | -0.1% | 0.69% | -0.6% |
| Q2 2019 | $2,667,000 | +8.3% | 18,660 | +0.0% | 0.69% | +6.2% |
| Q1 2019 | $2,463,000 | +27.4% | 18,659 | -0.5% | 0.65% | +12.8% |
| Q4 2018 | $1,934,000 | -9.6% | 18,759 | -4.7% | 0.58% | +7.3% |
| Q3 2018 | $2,139,000 | +10.0% | 19,687 | -0.1% | 0.54% | +4.3% |
| Q2 2018 | $1,944,000 | +0.8% | 19,697 | +0.0% | 0.52% | -4.6% |
| Q1 2018 | $1,928,000 | +6.5% | 19,696 | +0.9% | 0.54% | +8.2% |
| Q4 2017 | $1,811,000 | +5.0% | 19,516 | -2.9% | 0.50% | +5.1% |
| Q3 2017 | $1,724,000 | +1.7% | 20,092 | 0.0% | 0.48% | -0.6% |
| Q2 2017 | $1,696,000 | -1.3% | 20,092 | +0.0% | 0.48% | -6.1% |
| Q1 2017 | $1,718,000 | +11.6% | 20,091 | +1.5% | 0.51% | +3.7% |
| Q4 2016 | $1,540,000 | -13.4% | 19,788 | -12.7% | 0.49% | -20.7% |
| Q3 2016 | $1,778,000 | -22.4% | 22,676 | 0.0% | 0.62% | -24.5% |
| Q2 2016 | $2,290,000 | +6.5% | 22,676 | 0.0% | 0.82% | -0.1% |
| Q1 2016 | $2,151,000 | +2.1% | 22,676 | 0.0% | 0.82% | -4.4% |
| Q4 2015 | $2,106,000 | +8.5% | 22,676 | -0.5% | 0.86% | -0.1% |
| Q3 2015 | $1,941,000 | – | 22,781 | – | 0.86% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |